Geron Corporation (GERN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $606.81M
Last updated: Nov 17, 2026 at 4:32 PM ET
Geron Corporation (GERN) Statistics
Geron (GERN) has a market cap of $606.81M and an enterprise value of $658.07M. It kept -21.99% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 8.45% above the market cap, as debt exceeds cash.
| Market Cap | $606.81M |
|---|---|
| Enterprise Value | $658.07M |
| Latest price (Nov 17, 2026) | $1.00 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.1x and 3.0x. Its year-end P/S ranged from 30.0x to 566.3x from 2016 to 2024.
| P/S Ratio | 3.1x |
|---|---|
| Forward P/S | 2.6x |
| P/B Ratio | 3.0x |
Price Statistics
The stock is down 10.71% over 52 weeks and trades 13.79% below its 50-day average.
| Beta (1Y) | 1.42 |
|---|---|
| 52-Week Change | -10.71% |
| 1-Month Change | -16.67% |
| 3-Month Change | -37.11% |
| 6-Month Change | -18.03% |
| 5-Year Change | -41.92% |
| 10-Year Change | -51.65% |
| Total Return (1Y) | -10.71% |
| Total Return (3Y CAGR) | -20.22% |
| Total Return (5Y CAGR) | -7.42% |
| Return vs SPY (1Y) | -21.47% |
| Max Drawdown (1Y) | -54.13% |
| Max Drawdown (3Y) | -82.43% |
| Sharpe Ratio (1Y) | -0.16 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $1.16 |
| 200-Day Average | $1.40 |
| 52-Week Range | $0.84 to $2.01 |
| RSI (14 Days) | 44.7 |
| Average Volume (20 Days) | 19.09M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.31x current liabilities, and total debt is 0.53x shareholder equity.
| Current Ratio | 6.31x |
|---|---|
| Quick Ratio | 4.61x |
| Debt / Equity | 0.53x |
| Interest Coverage | -1.13x |
Returns and Efficiency
Return on invested capital is -7.40% over the last 12 months, against a 5-year average of -48.92%.
| Return on Equity (ROE) | -21.10% |
|---|---|
| Return on Assets (ROA) | -9.07% |
| Return on Invested Capital (ROIC) | -7.40% |
| Return on Capital Employed (ROCE) | -7.18% |
| ROE (5Y Average) | -88.55% |
| ROA (5Y Average) | -43.32% |
| ROIC (5Y Average) | -48.92% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 0.15x |
| Receivables Turnover | 4.46x |
| Cash Conversion Cycle | 2336 days |
Scores
GERN has an Altman Z-Score of -2.53, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.53 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $217.52M over the last 12 months is up 18.60% from the 12 months before.
| Revenue | $217.52M |
|---|---|
| Revenue Growth (YoY) | +18.60% |
| Gross Profit | $199.23M |
| Operating Income | -$32.08M |
| Pretax Income | -$47.83M |
| Net Income | -$47.83M |
| EBIT | -$32.50M |
| Reported EPS (TTM) | -$0.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 43.01% of the $527.11M in total assets.
| Cash and Equivalents | $69.18M |
|---|---|
| Total Debt | $120.44M |
| Net Debt | $51.26M |
| Net Debt Per Share | $0.08 |
| Working Capital | $394.49M |
| Shareholder Equity | $226.69M |
| Book Value Per Share | $0.34 |
| Total Assets | $527.11M |
| Total Liabilities | $300.41M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $661.00K of capital spending, operating cash flow left -$91.19M of free cash flow.
| Operating Cash Flow | -$90.53M |
|---|---|
| Capital Expenditures | $661.00K |
| Free Cash Flow | -$91.19M |
| FCF Per Share | -$0.14 |
| Depreciation and Amortization | $2.30M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -14.75%.
| Gross Margin | 91.59% |
|---|---|
| Operating Margin | -14.75% |
| Pretax Margin | -21.99% |
| Net Margin | -21.99% |
| EBIT Margin | -14.94% |
| FCF Margin | -41.92% |
Growth
| Revenue Growth (5Y CAGR) | +273.49% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -9.87% |
| Tangible Book Per Share Growth (2Y CAGR) | -9.87% |
Dividends and Yields
GERN does not pay a dividend. Its free cash flow yield is -13.56%.
| FCF Yield | -13.56% |
|---|---|
| Buyback Yield | -0.72% |
| Shareholder Yield | -0.72% |
Peer Position
Against 5 similar companies, GERN has the 4th highest P/S.
P/S RatioPeer median 4.0x
ROICPeer median -11.69%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -66.55%
| P/S Ratio | 3.1x vs 4.0x median |
|---|---|
| ROIC | -7.40% vs -11.69% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +18.60% vs -66.55% median |
Analyst Forecast
Consensus estimates put revenue growth at 35.59% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +35.59% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GERN
What is GERN's market cap?
Geron has a market cap of $606.81M. Its enterprise value, which adds debt and subtracts cash, is $658.07M.
How many shares of GERN are outstanding?
Geron has 672.29M shares outstanding. The count is up 0.78% from a year earlier.
Does GERN pay a dividend?
No. Geron does not pay a dividend.
How much debt does GERN have?
Geron has $120.44M of total debt and $69.18M of cash and equivalents, a net debt position of $51.26M.
GERN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors